quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:31:07·254d
SECFiling
Spero Therapeutics Inc. logo

SEC Form 10-Q filed by Spero Therapeutics Inc.

SPRO· Spero Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • SPRO
    Spero Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 20UpdateEvercore ISI$5.00
  • Sep 23UpdateEvercore ISI$8.00
  • Oct 1UpdateOppenheimer-

Related

  • SEC10d
    SEC Form PRE 14A filed by Spero Therapeutics Inc.
  • SEC28d
    Spero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
  • SEC28d
    SEC Form 10-K filed by Spero Therapeutics Inc.
  • PR28d
    Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
  • PR36d
    Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
  • INSIDER73d
    Officer Rajavelu Esther sold $207,484 worth of shares (87,917 units at $2.36), decreasing direct ownership by 8% to 1,012,091 units (SEC Form 4)
  • INSIDER73d
    Chief Operating Officer Keutzer Timothy sold $44,019 worth of shares (18,652 units at $2.36), decreasing direct ownership by 2% to 742,506 units (SEC Form 4)
  • INSIDER77d
    Chief Operating Officer Keutzer Timothy was granted 68,000 shares and sold $101,175 worth of shares (46,586 units at $2.17), increasing direct ownership by 3% to 761,158 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022